REYKJAVIK, Iceland, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and…
Mynzepli® (aflibercept) is approved in all European Economic Area member countries for the treatment of various retinal diseases including neovascular…
Luxembourg (July 3, 2025) – Alvotech S.A. announces that on June 25, 2025, the proportion of own shares held by…
REYKJAVIK, Iceland, June 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the…
THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG…